Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care

Pathology

Volumn 45, Issue 4, 2013, Pages 357-370

  Trent, Ronald J ^a,b   Cheong, Pak Leng ^a,b   Chua, Eng Wee ^c,d   Kennedy, Martin A ^c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Drug efficacy; Drug safety; Genetic testing; Molecular diagnostics; Personalised medicine; Pharmacogenetics; Pharmacogenomics

Indexed keywords

EID: 84879640273     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e328360b66e     Document Type: Article

References (120)

1. National Center for Biotechnology Information (NCBI). A science primer: defining pharmacogenetics and pharmacogenomics. 31 Mar 2004; cited 16 Nov 2012. www.ncbi.nlm.nih.gov/About/primer/pharm.html.
2. Cambridge Healthtech Institute. -Omes and -omics glossary and taxonomy. 23 Mar 2012; cited 16 Nov 2012. www.genomicglossaries.com/content/omes.asp.
3. Daly AK. Pharmacogenetics and human genetic polymorphisms. Biochem J 2010; 429: 435-9.
4. Lima JJ, Blake KV, Tantisira KG, Weiss ST. Pharmacogenetics of asthma. Curr Opin Pulm Med 2009; 15: 1-11.
5. Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234-42.
6. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 2004; 329: 15-9.
7. Australian Law Reform Commission (ALRC). Essentially yours: the protection of human genetic information in Australia. ALRC report 96. 30 May 2003, modified 19 Jul 2012; cited 16 Nov 2012. www.alrc.gov.au/publications/ report-96.
8. Trent RJ. Direct to consumer (DTC) DNA testing - clinical considerations. Med J Aust 2013; 198: (in press).
9. Chua EW, Kennedy MA. Current state and future prospects of direct-toconsumer pharmacogenetics. Front Pharmacol 2012; 3: 1-8.
10. Genelex. Welcome to Genelex. Cited 16 Nov 2012. http://genelex.com/.
11. van der Straaten T, Guchelaar H-J, Swen JJ. The challenges of developing a 'medical-grade' genome. Pharmacogenomics 2012; 13: 369-72.
12. Need AC, Shashi V, Hitomi Y, et al. Clinical application of exome sequencing in undiagnosed genetic conditions. J Med Genet 2012; 49: 353-61.
13. Pulley JM, Denny JC, Peterson JF, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012; 92: 87-95.
14. Wolf SM, Lawrenz FP, Nelson CA, et al. Managing incidental findings in human subjects research: analysis and recommendations. J Law Med Ethics 2008; 36: 219-48.
15. Wolf SM, Crock BN, Van Ness B, et al. Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet Med 2012; 14: 361-84.
16. US Food and Drug Administration (FDA). Class II Special Controls Guidance Document: Drug Metabolizing Enzyme Genotyping System - Guidance for Industry and FDA Staff. 10 Mar 2005; cited 16 Nov 2012. www.fda.gov/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ucm077933.htm.
17. Weiss RL. The long and winding regulatory road for laboratory-developed tests. Am J Clin Pathol 2012; 138: 20-6.
18. National Center for Biotechnology Information. Genetic Testing Registry. Cited 16 Nov 2012. www.ncbi.nlm.nih.gov/gtr/.
19. US Food and Drug Administration (FDA). Table of pharmacogenomic biomarkers in drug labels. Cited 16 Nov 2012. www.fda.gov/drugs/scienceresearch/ researchareas/pharmacogenetics/ucm083378.htm.
20. US Food and Drug Administration (FDA). FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. 25 Mar 2010; cited 16 Nov 2012. www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm.
21. US Food and Drug Administration (FDA). Information for Healthcare Professionals: abacavir (marketed as Ziagen) and abacavir-containing medications. 3 Nov 2009; cited 16 Nov 2012. www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm123927.htm.
22. US Food and Drug Administration (FDA). Information for Healthcare Professionals: dangerous or even fatal skin reactions - carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). 15 Mar 2011; cited Nov 2012. www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718.htm.
23. US Food and Drug Administration (FDA). Approved Risk Evaluation and Mitigation Strategies (REMS). Cited 16 Nov 2012. www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm.
24. US Food and Drug Administration (FDA). Medication Guides. Cited 16 Nov 2012. www.fda.gov/Drugs/DrugSafety/ucm085729.htm.
25. Therapeutic Goods Administration. IVD guidance documents. 29 Feb 2012; cited 16 Nov 2012. www.tga.gov.au/industry/ivd-guidance.htm.
26. Therapeutic Goods Administration. ANZTPA Implementation Ministerial Council communiqué. 28 Jan 2012; cited 16 Nov 2012. www.tga.gov.au/about/ international-anztpa-imc-120128.htm.
27. GAPP Knowledge Base. An integrated, searchable knowledge base of genomic applications in practice and prevention (GAPP). Cited 16 Nov 2012. www.hugenavigator.net/GAPPKB/home.do.
28. Khoury MJ, Feero WG, Reyes M, et al. The Genomic Applications in Practice and Prevention Network. Genet Med 2009; 11: 488-94.
29. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPPWorking Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med 2009; 11: 66-73.
30. Thakur M, Grossman I, McCrory DC, et al. Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet Med 2007; 9: 826-35.
31. Palomaki GE, Bradley LA, Douglas MP, et al. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 2009; 11: 21-34.
32. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010; 11: 241-6.
33. International Serious Adverse Events Consortium (iSAEC). Cited 16 Nov 2012. www.saeconsortium.org/.
34. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-9.
35. Thorn CF, Klein TE, Altman RB. Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics 2010; 11: 501-5.
36. PharmGKB. Consortia. Cited 16 Nov 2012. www.pharmgkb.org/projects.Jsp.
37. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89: 464-7.
38. Clinical and Translational Science Institute University of Florida. Personalised Medicine Program. Cited 16 Nov 2012. www.ctsi.ufl.edu/about/ctsi- programs/personalized-medicine/.
39. O'Donnell PH, Bush A, Spitz J, et al. The 1200 Patients Project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther 2012; 92: 446-9; http://cpt.uchicago.edu/page/1200-patients- project.
40. Swen JJ, Wilting I, de Goede AL, et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther 2008; 83: 781-7.
41. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte - an update of guidelines. Clin Pharmacol Ther 2011; 89: 662-73.
42. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91: 321-6.
43. Wilke RA, Ramsey LB, Johnson SG, et al. The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012; 92: 112-7.
44. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89: 387-91.
45. Martin MA, Klein TE, Dong BJ, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 2012; 91: 734-8.
46. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90: 328-32.
47. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011; 90: 625-9.
48. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 2013; 93: 153-8.
49. Johnson JA, Roden DM, Lesko LJ, et al. Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther 2012; 91: 774-6.
50. Holmes DR, Dehmer GJ, Kaul S, et al. CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA 'Boxed Warning': a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010; 122: 537-57.
51. Nissen SE. Pharmacogenomics and clopidogrel: irrational exuberance? JAMA 2011; 306: 2727-8.
52. Bauer T, Bouman HJ, Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. Br Med J 2011; 343: d4588.
53. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogreltreated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic metaanalysis. J Am Coll Cardiol 2010; 56: 134-43.
54. Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events. JAMA 2011; 306: 2704-14.
55. PharmGKB. Translational Pharmacogenetics Project (TPP) Look Up Tables By Gene. Cited 16 Nov 2012. www.pharmgkb.org/page/tppTables.
56. Crews KR, Cross SJ, McCormick JN, et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 2011; 68: 143-50.
57. McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N Engl J Med 2011; 364: 340-50.
58. US Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS). 2011 Report on Genetics Education and Training. Feb 2011; cited 16 Nov 2012. http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS-education-report-2011. pdf.
59. Gurwitz D, Lunshof JE, Dedoussis G, et al. Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics 2005; 5: 221-5.
60. Green JS, O'Brien TJ, Chiappinelli VA, et al. Pharmacogenomics instruction in US and Canadian medical schools: implications for personalized medicine. Pharmacogenomics 2010; 11: 1331-40.
61. Higgs JE, Andrews J, Gurwitz D, et al. Pharmacogenetics education in British medical schools. Genomic Med 2008; 2: 101-5.
62. Stanek EJ, Sanders CL, Taber KA, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther 2012; 91: 450-8.
63. Kennedy MA, Joyce PR, Begg EJ. Institutional profile: The Carney Centre for Pharmacogenomics: a New Zealand focus for personalized medicine research. Pharmacogenomics 2012; 13: 865-8.
64. University of California San Diego. Pharmacogenomics Education Program. Cited 16 Nov 2012. http://pharmacogenomics.ucsd.edu/.
65. Australian Centre for Health Research. Healthcare in Australia: Prescriptions for Improvement. Melbourne: Australian Centre for Health Research, 2011. www.achr.com.au/.
66. PharmGKB. The Pharmacogenomics Knowledge Base. Cited 16 Nov 2012. www.pharmgkb.org.
67. PharmGKB. Dosing guidelines. Cited 16 Nov 2012. www.pharmgkb.org/search/ guidelineList.action.
68. Hicks JK, Crews KR, Hoffman JM, et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther 2012; 92: 563-6.
69. Kullo IJ, Jarvik GP, Manolio TA, et al. Leveraging the electronic health record to implement genomic medicine. Genet Med 2012 Sep 27. Epub ahead of print.
70. Dolgin E. Preemptive genotyping trialed to prevent adverse drug reactions. Nat Med 2011; 17: 1323.
71. Thomson Reuters. Press Releases: GenoSpace Joins Thomson Reuters Life Sciences Partner Ecosystem. 15 Aug 2012; cited 16 Nov 2012. http:// thomsonreuters.com/content/press-room/science/710259.
72. Open Personal Genomics Consortium (OpenPgx). Cited 16 Nov 2012. www.openpgx.org.
73. Karczewski KJ, Tirrell RP, Cordero P, et al. Interpretome: a freely available, modular, and secure personal genome interpretation engine. Pac Symp Biocomput 2012; 339-50. http://esquilax.stanford.edu/.
74. Illumina Inc. MyGenome iPhone application. Cited 16 Nov 2012. https://itunes.apple.com/us/app/mygenome/id516405838?mt=8.
75. European Commission Joint Research Centre, European Science and Technology Observatory, Institute for Prospective Technological Studies. Pharmacogenetics and Pharmacogenomics: State-of-the-Art and Potential Socio-Economic Impact in the EU. Technical report series 2006. Luxembourg: European Communities, 2006. http://ftp.jrc.es/EURdoc/eur22214en.pdf.
76. US President's Council of Advisors on Science and Technology. Priorities for Personalized Medicine. Sep 2008; cited 16 Nov 2012. www.whitehouse.gov/ files/documents/ostp/PCAST/pcast-report-v2.pdf.
77. House of Lords Science and Technology Committee. Genomic Medicine. Volume 1: Report. London: The Stationery Office Limited, 2009. www.publications. parliament.uk/pa/ld200809/ldselect/ldsctech/107/107i.pdf.
78. UK Department of Health. Building on our inheritance: genomic technology in healthcare. 25 Jan 2012; cited 15 Nov 2012. www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-132369.
79. PHG Foundation. Genomics in Medicine: Delivering Genomics Through Clinical Practice. Report of the Joint Committee on Medical Genetics. Cambridge: PHG Foundation, 2012. www.phgfoundation.org/reports/12093/.
80. Aihara M. Pharmacogenetics of cutaneous adverse drug reactions. J Dermatol 2011; 38: 246-54.
81. Marchant GE, Campos-Outcalt DE, Lindon RA. Physician liability: the next big thing for personalized medicine? Pers Med 2011; 8: 457-67.
82. Anderson MW, Schrijver I. Next generation DNA sequencing and the future of genomic medicine. Genes 2010; 1: 38-69.
83. The official site of the British Prime Minister's Office. DNA tests to revolutionise fight against cancer and help 100, 000 NHS patients. 10 Dec 2012; cited 23 Jan 2013. www.number10.gov.uk/news/dna-tests-to-fightcancer/.
84. Regulating pharmacogenomics: an overview of developments in various countries and industry response to regulatory initiatives. A report for Health Canada. 2006; cited 18 Nov 2012. http://genevalues.files.wordpress.com/2012/01/ regulating-pharmacogenomics-report-for-health-canada2.pdf.
85. Evans JP, Berg JS. Next-generation DNA sequencing, regulation and the limits of paternalism. JAMA 2011; 306: 2376-7.
86. US Food and Drug Administration (FDA). Draft Guidance for Industry: Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling Draft Guidance. 17 Feb 2011; cited 23 Jan 2013. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM243702.pdf.
87. Industry PharmacogenomicsWorking Group (I-PWG). Cited 23 Jan 2013. www.i-pwg.org/.
88. Genetics Home Reference. CYP gene family: What are the CYP genes? Cited 16 Nov 2012. http://ghr.nlm.nih.gov/geneFamily/cyp.
89. Daly AK. Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects. Adv Pharm 2012; 63: 137-67.
90. Australian Government Department of Health and Ageing. Co-dependent and hybrid technologies. 29 Nov 2011; cited 16 Nov 2012. www.health.gov.au/internet/ hta/publishing.nsf/Content/co-1.
91. Naylor S, Cole T. Overview of companion diagnostics in the pharmaceutical industry. Drug Discov World Spring 2010; 67-79.
92. Valdes R, Payne D, Linder MW, editors. Laboratory Medicine Practice Guidelines. Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice. Washington, DC: National Academy of Clinical Biochemistry, American Association for Clinical Chemistry, 2010.
93. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. C-16. 28 Mar 2012; cited 16 Nov 2012. http://aidsinfo.nih.gov/ contentfiles/lvguidelines/adultandadolescentgl.pdf.
94. National Comprehensive Cancer Network (NCCN). NCCN Guidelines. Cited 16 Nov 2012. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
95. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
96. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-83.
97. Lubitz SA, Scott SA, Rothlauf EB, et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost 2010; 8: 1018-26.
98. Gnant M, Harbeck N, Thompssen C. St Gallen 2011: summary of the consensus discussion. Breast Care 2011; 6: 136-41.
99. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3784-96.
100. Abraham JE, Maranian MJ, Driver KE, et al. CYP2D6 gene variant: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. BMC 2010; 12: R64.
101. Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012; 104: 452-60.
102. Regan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 Trial. J Natl Cancer Inst 2012; 104: 441-51.
103. Pharmacovigilance Working Party (PhVWP). PhVWP monthly report on safety concerns, guidelines and general matters. July 2012, Issue No 1207. Cited 15 Nov 2012. www.ema.europa.eu/docs/en-GB/document-library/Report/2012/07/WC500130391. pdf.
104. Chen HY, Chen LC. Implementation of innovative pharmacogenetic tests into practice in Taiwan: an institutional perspective. Drug Dev Res 2010; 71: 502-6.
105. Pharmacovigilance Working Party (PhVWP). PhVWP monthly report. November 2009, Issue No 0911. Cited 15 Nov 2012. www.emea.europa.eu/docs/en-GB/document- library/Report/2012/07/WC500130391.pdf.
106. PharmGKB. Drug labels. Cited 15 Nov 2012. www.pharmgkb.org/search/ labelList.action.
107. Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118: 1208-15.
108. PharmGKB. CPIC dosing guideline - thioguanine, TPMT. Cited 16 Nov 2012. www.pharmgkb.org/drug/PA451663.
109. Royal College of Pathologists of Australasia (RCPA). RCPA catalogue of genetic tests and laboratories. Cited 16 Nov 2012. http://genetictesting.rcpa. edu.au/.
110. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-31.
111. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-64.
112. Shaw PB, Donovan JL, Tran MT, et al. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. J Thromb Thrombolysis 2010; 30: 220-5.
113. Wafarin Dosing. Cited 16 Nov 2012. www.warfarindosing.org.
114. Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 2012; 125: 1997-2005.
115. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-12.
116. Sagreiya H, Berube C, Wen A, et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics 2010; 20: 407-13.
117. King CR, Deych E, Milligan P, et al. Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 2010; 104: 750-4.
118. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 2010; 87: 572-8.
119. Horne BD, Lenzini PA, Wadelius M, et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost 2012; 107: 232-40.
120. Borobia AM, Lubomirov R, Ramirez E, et al. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. PLoS One 2012; 7: e41360.